Speaker Profile
Ph.D., CBO, Insilico Medicine
Biography
Michelle Chen is the Chief Business Officer at Insilico Medicine, a leader in the AI-powered drug discovery and development field. She is responsible for the companys global strategies, business and corporate development, and the US operations. As a biotech executive, Michelle brings in 20+ years of global experience in biopharma and tech-bio industries, having worked at multi-national companies such as Roche, Merck, BioMarin, Agilent, as well as small biotech companies. She has a strong track record of success in company building, BDL, MA, RD, marketing, and product commercialization. Michelle obtained her Ph.D. in Biochemistry from the University of Washington, did her postdoctoral work at UCSF, and received Bioinformatics training at Stanford.
Session Abstract – PMWC 2025 Silicon Valley
Track Chair:
- William Oh, Yale Cancer Center
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- PMWC 2025 Award Ceremony
Pioneer Honoree: Isaac Kohane, Harvard
- Keynote: Can AI succeed where humans have failed to personalize medicine?
- Isaac Kohane, Harvard
- From Data to Decisions: Real-Time Patient Insights for Improved Care (PANEL)
Chair: Michael Pfeffer, Stanford Medicine
- Chris Longhurst, UC San Diego Health
- Tanya Townsend, Stanford Children’s
- Kiran Mysore, Sutter Health
- Cherodeep Goswami, UW Health - AI-Powered RWE: Driving Trustworthy Insights and Innovation through Interoperability (PANEL)
Chair: Charles Jaffe, HL7 International
- Chris Longhurst, UC San Diego Health
- Donald Rucker, 1upHealth
- Stan Huff, Graphite Health
- John Ioannidis, Stanford
- Chris Boone, Oracle
- Accelerating Drug Development with Real World Evidence and AI: Amgen's Journey
- Brian Bradbury, Amgen
- AI-Powered RWE: Accelerating Drug Development and Post-Market Applications (PANEL)
Chair: Erik Reinertsen, Demand Discovery Group
- Michelle Chen, Insilico Medicine
- Jun Jeon, Khosla Ventures
- Dan Riskin, Verantos
- Andrew Trister, Verily - Advancing Patient-Centered Outcomes with AI and Real-World Data Integration
- Phil Johnson, Evidation Health
- Leveraging AI and Real-World Evidence to Transform Patient Care in Oncology
- Amrita Basu, UCSF
- How to Implement AI for Faster Readout of Clinical Trails
Chair:William Oh, Yale
- Jennifer Webster, Pfizer
- Brandon Allgood, Parabilis Medicines
- Julian Hong, UCSF
- Michiel Niesen, nference
